T Cell Nouveau logo

T Cell Nouveau

Clinical stage biopharmaceutical company with novel TCR like CAR-T cell therapy for solid tumors at affordable price

1 employees · est. 2021 · Tokyo, Japan

VS
Zelluna Immunotherapy logo

Zelluna Immunotherapy

Developing allogeneic TCR-NK therapies for solid tumors

25 employees · est. 2016 · Oslo, Norway

Zelluna Immunotherapy is the older company (2021 vs 2016); Zelluna Immunotherapy is the larger of the two.

Side-by-Side Comparison

T Cell Nouveau Zelluna Immunotherapy
Founded
2021 2016 older
Headquarters
Tokyo, Japan Oslo, Norway
Employees
1 25 larger
Industry
Biopharma, Biotechnology Biotechnology, Health Care, Pharmaceutical
Funding Stage
Not tracked yet Series Unknown
Total Funding
Not tracked yet $7.50M
Funding Rounds
Not tracked yet 4
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, TCR-T Cell Therapy, CAR-T Cell Therapy, Immunotherapy, Solid Tumors, Oncoimmunotherapy, Oncology, Cell Therapy, Cancer Therapy, Neoantigen, MAGEA4, PRAME, Head And Neck Cancer, HLA02, Cancer Vaccine Immunotherapy, Cancer Treatment, Adoptive Cell Therapy, T Cell Receptor Technologies, Solid Tumors, Biopharmaceutical, Cellular Therapy, Allogeneic TCR-NK Therapies, GMP Facilities, Oslo Cancer Cluster, Norwegian Radium Hospital, Research And Development, Immunooncology, Norwegian Biotechnology
Website
tcellnouveau.com zelluna.com
T Cell Nouveau logo

About T Cell Nouveau

T Cell Nouveau is a clinical stage biopharmaceutical company based in Japan that aims to revolutionize cancer treatment. Their mission is to provide affordable TCR like CAR-T cell therapies for common cancers, making it accessible to common people. The company's proprietary technology, originating f...

Zelluna Immunotherapy logo

About Zelluna Immunotherapy

Zelluna is a Norway-based biotechnology company founded in 2016. The company is focused on pioneering allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. Zelluna's slogan "Developing allogeneic TCR-NK therapies for solid tumors" encaps...

We will tell you when either one moves

BounceWatch watches T Cell Nouveau and Zelluna Immunotherapy for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at T Cell Nouveau and Zelluna Immunotherapy — by email.

Frequently Asked Questions

T Cell Nouveau — Clinical stage biopharmaceutical company with novel TCR like CAR-T cell therapy for solid tumors at affordable price. Zelluna Immunotherapy — Developing allogeneic TCR-NK therapies for solid tumors. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
T Cell Nouveau has raised undisclosed funding while Zelluna Immunotherapy has raised $7.50M.
T Cell Nouveau and Zelluna Immunotherapy operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare T Cell Nouveau with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at T Cell Nouveau on 12 Sep 2024, and Zelluna Immunotherapy on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy